Alzheimer's Drugs Market Size, Share, Forecast, & Trends Analysis by Drug (Cholinesterase Inhibitor, NMDA Receptor, Glutamate Regulator) Application (Disease Progression, Symptom Management)

Description

List of Tables

Alzheimer's Drugs Market Size, Share, Forecast, & Trends Analysis by Drug (Cholinesterase Inhibitor [Donepezil, Galantamine, Rivastigmine], NMDA Receptor, Glutamate Regulator) Application (Disease Progression, Symptom Management)-Global Forecast to 2031

The Alzheimer's Drugs Market is Projected to Reach $9.62 Billion by 2031 at a CAGR of 9.8% From 2024 to 2031.

Succeeding extensive secondary and primary research and in-depth analysis of the market scenario, the report comprises the analysis of key industry drivers, restraints, challenges, and opportunities. The growth of this market can be attributed to various factors, such as the increasing burden of Alzheimer's disease globally, rising prevalence of risk factors, increase in research funding, introduction of innovative technologies, increasing number of approvals, and increasing number of clinical trials and pipeline products. However, possible side effects of drugs and the use of substitute treatments are restraining the market growth.

Furthermore, growing research activities in developing countries, an increase in awareness programs, initiatives by public and private organizations, the use of combination drug therapy, and the use of biomarkers and imaging techniques for diagnosis and management are expected to offer growth opportunities to the players operating in this market. However, the high cost of research and development, the high failure rate in clinical trials, and the lengthy and complex regulatory approval process for Alzheimer's drugs are major challenges to the market's growth.

The report offers a competitive landscape based on an extensive assessment of the product portfolio offerings, geographic presences, and key strategic developments adopted by leading market players in the industry over four years (2020-2024). The key players operating in the Alzheimer's drugs market are Biogen (U.S.), Novartis AG (Switzerland), F. Hoffmann-La Roche AG (Switzerland), AbbVie Inc. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Eisai Co., Ltd. (Japan), Supernus Pharmaceuticals Inc. (U.S.), H. Lundbeck A/S (Denmark), AC Immune SA (Switzerland), Zydus Lifesciences Limited (India), Johnson & Johnson (U.S.), and Daiichi Sankyo Company (Japan).

Among all the drug types studied in this report, in 2024, the cholinesterase inhibitors segment is expected to account for the largest share of 46.9% of the Alzheimer's drugs market. The cholinesterase inhibitors segment is further divided into donepezil, galantamine, and rivastigmine. The large share of the segment is attributed to the rising prevalence of Alzheimer's disease, the increasing aging population, rising approval for cholinesterase inhibitors, and the increasing effectiveness of drugs. Additionally, donepezil is used to treat all the stages of Alzheimer's disease, that is, early, middle, and late, further increasing the demand for these drugs, thus contributing to the largest share of the segment.

Among all the applications studied in this report, in 2024, the symptom management segment is expected to account for the largest share of the Alzheimer's drugs market. The symptom management segment is further divided into dementia, insomnia, and other symptoms. The large share of the segment is attributed to the availability of a greater number of symptom-management drugs compared to disease progression and increasing focus on symptom management. The focus on symptom management is increasing to slower the disease progression to reduce the cost and healthcare resources associated with it. Additionally, symptom management improves the patient's quality of life, reduces dependency on caregivers, and improves patient safety by addressing the symptoms of dementia, impaired judgment, and confusion symptoms.

An in-depth analysis of the geographical scenario of the global Alzheimer's drugs market provides detailed qualitative and quantitative insights into the five major geographies (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region. In 2024, North America is expected to account for the largest share of the Alzheimer's drugs market. The largest share of the region is attributed to the increasing prevalence of Alzheimer's disease, rising number of clinical trials for Alzheimer's drugs, increasing funding for the development of Alzheimer's drugs, and increasing awareness programs. Also, supportive government initiatives to reduce the prevalence of Alzheimer's disease are further contributing to the largest share of the segment. For instance, the U.S. Department of Health and Human Services signed a law, namely, the National Alzheimer's Project Act (NAPA). The objective of NAPA is to prevent and effectively treat Alzheimer's disease by 2025.

Scope of the Report:

Alzheimer's Drug Market Assessment-by Drug Type

Cholinesterase Inhibitors
- Donepezil
- Galantamine
- Rivastigmine
NMDA Receptor Antagonists
Glutamate regulators
Combination Drugs

Alzheimer's Drug Market Assessment-by Application

Disease Progression
Symptoms Management
- Dementia
- Insomnia
- Other Symptoms

Note: Other symptoms include loss of spontaneity, depression, hallucination, or paranoia.

Alzheimer's Drug Market Assessment-by Geography

North America
- U.S.
- Canada
Europe
- Germany
- France
- U.K
- Italy
- Spain
- Switzerland
- Belgium
- Rest of Europe (RoE)
Asia-Pacific (APAC)
- China
- Japan
- India
- South Korea
- Rest of Asia-Pacific (RoAPAC)
Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
Middle East & Africa
- UAE
- Saudi Arabia
- South Africa
- Rest of the Middle East & Africa

Product Code: MRHC - 1041264

1. Introduction

1.1. Market Definition & Scope
1.2. Market Ecosystem
1.3. Currency & Limitations
1.4. Key Stakeholders

2. Research Methodology

2.1. Research Approach
2.2. Process of Data Collection & Validation
- 2.2.1. Secondary Research
- 2.2.2. Primary Research/Interviews with Key Opinion Leaders of the Industry
2.3. Market Sizing and Forecasting
- 2.3.1. Market Size Estimation Approach
- 2.3.2. Growth Forecast Approach
- 2.3.3. Market Share Analysis
2.4. Assumptions for the Study

3. Executive Summary

4. Market Insights

4.1. Overview
4.2. Drivers
- 4.2.1. Increasing Burden of Alzheimer's Disease Globally
- 4.2.2. Rising Prevalence of Risk Factors
- 4.2.3. Increase in Research Funding
- 4.2.4. Introduction of Innovative Technologies
- 4.2.5. Increasing Number of Approvals
- 4.2.6. Increasing Number of Clinical Trials and Pipeline Products
4.3. Restraints
- 4.3.1. Possible Side Effects of Drugs
- 4.3.2. Use of Substitute Treatment
4.4. Opportunities
- 4.4.1. Growing Research Activities in Developing Countries
- 4.4.2 Increase in Awareness Programs
- 4.4.3. Initiatives by Public and Private Organizations
- 4.4.4. Use of Combination Drug Therapy
- 4.4.5. Use of Biomarkers and Imaging Techniques for Diagnosis and Management
4.5. Challenges
- 4.5.1. High Cost of Research and Development for Alzheimer's Drugs
- 4.5.2. High Failure Rate in Clinical Trials for Alzheimer's Drugs
- 4.5.3. Lengthy and Complex Regulatory Approval Process for Alzheimer's Drugs
4.6. Factor Analysis
4.7. Trends
4.8. Regulatory Analysis
4.9. Pricing Analysis
4.10. Pipeline Analysis
4.11. Porter's Five Force Analysis

5. Alzheimer's Drugs Market Assessment-by Drug Type

5.1. Overview
5.2. Cholinesterase Inhibitors
- 5.2.1. Donepezil
- 5.2.2. Galantamine
- 5.2.3. Rivastigmine
5.3. NMDA receptor antagonists
5.4. Glutamate regulators
5.5. Combination Drugs

6. Alzheimer's Drugs Market Assessment-by Application

6.1. Overview
6.2. Disease Progression
6.3. Symptoms Management
- 6.3.1. Dementia
- 6.3.2. Insomnia
- 6.3.3. Other Symptoms

7. Alzheimer's Drugs Market Assessment-by Geography

7.1. Overview
7.2. North America
- 7.2.1. U.S.
- 7.2.2. Canada
7.3. Europe
- 7.3.1. Germany
- 7.3.2. France
- 7.3.3. U.K.
- 7.3.4. Italy
- 7.3.5. Spain
- 7.3.6. Switzerland
- 7.3.7. Belgium
- 7.3.8. Rest of Europe (RoE)
7.4. Asia-Pacific
- 7.4.1. Japan
- 7.4.2. China
- 7.4.3. India
- 7.4.4. South Korea
- 7.4.5. Rest of Asia-Pacific (RoAPAC)
7.5. Latin America
- 7.5.1. Brazil
- 7.5.2. Mexico
- 7.5.3. Argentina
- 7.5.4. Rest of Latin America (RoLATAM)
7.6. Middle East & Africa
- 7.6.1. UAE
- 7.6.2. Saudi Arabia
- 7.6.3. South Africa
- 7.6.4. Rest of Middle East & Africa

8. Competition Analysis

8.1. Overview
8.2. Key Growth Strategies
8.3. Competitive Benchmarking
8.4. Competitive Dashboard
- 8.4.1. Industry Leaders
- 8.4.2. Market Differentiators
- 8.4.3. Vanguards
- 8.4.4. Emerging Companies
8.5. Market Share Analysis/Market Ranking, by Key Players (2023)

9. Company Profiles (Company Overview, Financial Overview, Product Portfolio, and Strategic Developments)

9.1. Biogen
9.2. Novartis AG
9.3. F. Hoffmann-La Roche AG
9.4. AbbVie Inc.
9.5. Teva Pharmaceutical Industries Ltd.
9.6. Eisai Co., Ltd.
9.7. SUPERNUS PHARMACEUTICALS, INC.
9.8. H. Lundbeck A/S
9.9. AC Immune SA
9.10. Zydus Lifesciences Limited
9.11. Johnson & Johnson
9.12. Daiichi Sankyo Company

(Note: SWOT analyses of the top 5 companies will be provided.)

10. Appendix

10.1. Available Customization
10.2. Related Reports